IMV Phase 2 Trial Results Coming

IMV Inc., the Dartmouth company developing a delivery platform for immunotherapy drugs, is entering a critical phase of its 16-year history as it will soon learn the results of key Phase 2 clinical trials.
The company is conducting a range of Phase 2 trials for its flagship drug candidate DPX-Survivac, including tests in partnership with the multi-national pharma company Merck & Co. The results